Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07108894 | A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants | PHASE1 | RECRUITING | 40 | — | — | Jul 25, 2025 | Apr 1, 2027 | Mar 23, 2026 | 1 | Canada |
| Arm | Type | Description |
|---|---|---|
| ABCL575 | EXPERIMENTAL | Healthy participants will receive a single dose of ABCL575 administered by subcutaneous (SC) injection |
| Placebo | PLACEBO_COMPARATOR | Healthy participants will receive a single dose of placebo administered by subcutaneous (SC) injection |
| Name | Type | Description |
|---|---|---|
| ABCL575 | BIOLOGICAL | Participants will receive SC injection of ABCL575 |
| Placebo (Normal Saline 0.9%) | BIOLOGICAL | Participants will receive SC injection of placebo (Normal Saline 0.9%) |
Inclusion Criteria: * Healthy male or female ≥ 18 and ≤ 65 years of age at the time of screening * Good general health as determined through medical history and general physical examination * Body weight ≥ 50 and ≤ 100 Kg * Body mass index (BMI) between 18.5 kg/m2 and 30.0 kg/m2 * Non- or ex-smoker...